BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 9156283)

  • 1. Genetics of renal tumours.
    Fleming S
    Cancer Metastasis Rev; 1997 Jun; 16(1-2):127-40. PubMed ID: 9156283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
    Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
    Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in the molecular basis of renal neoplasia.
    Cohen HT
    Curr Opin Nephrol Hypertens; 1999 May; 8(3):325-31. PubMed ID: 10456263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inherited renal cancer.
    Turner KJ
    BJU Int; 2000 Jul; 86(2):155-64;quiz i. PubMed ID: 10886102
    [No Abstract]   [Full Text] [Related]  

  • 5. [VHL, angiogenesis and renal carcinoma: the puzzle is complete].
    Richard S
    Ann Pathol; 2000 Mar; 20(2):107-9. PubMed ID: 10740003
    [No Abstract]   [Full Text] [Related]  

  • 6. Germline and somatic mutations in von Hippel-Lindau disease gene and its significance in the development of kidney cancer.
    Shuin T; Kondo K; Ashida S; Okuda H; Yoshida M; Kanno H; Yao M
    Contrib Nephrol; 1999; 128():1-10. PubMed ID: 10597373
    [No Abstract]   [Full Text] [Related]  

  • 7. The von Hippel-Lindau tumor suppressor gene. A rare and intriguing disease opening new insight into basic mechanisms of carcinogenesis.
    Decker HJ; Weidt EJ; Brieger J
    Cancer Genet Cytogenet; 1997 Jan; 93(1):74-83. PubMed ID: 9062583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Von Hippel-Lindau disease and sporadic renal cell carcinoma.
    Zbar B
    Cancer Surv; 1995; 25():219-32. PubMed ID: 8718521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Von Hippel-Lindau disease: the role of gene analysis in affected families.
    Riegler P; Huber W; Corradini R; Neumann HP; Glaesker S; Sessa A
    Nephron; 2000 Jan; 84(1):95-7. PubMed ID: 10644921
    [No Abstract]   [Full Text] [Related]  

  • 11. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling.
    Wykoff CC; Pugh CW; Maxwell PH; Harris AL; Ratcliffe PJ
    Oncogene; 2000 Dec; 19(54):6297-305. PubMed ID: 11175344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythropoietin, tumours and the von Hippel-Lindau gene: towards identification of mechanisms and dysfunction of oxygen sensing.
    Wiesener MS; Eckardt KU
    Nephrol Dial Transplant; 2002 Mar; 17(3):356-9. PubMed ID: 11865075
    [No Abstract]   [Full Text] [Related]  

  • 14. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
    Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER
    Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
    Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG
    Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour suppression by the human von Hippel-Lindau gene product.
    Iliopoulos O; Kibel A; Gray S; Kaelin WG
    Nat Med; 1995 Aug; 1(8):822-6. PubMed ID: 7585187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of chromosome 3p12-p21 tumour suppressor genes in clear cell renal cell carcinoma: analysis of VHL dependent and VHL independent pathways of tumorigenesis.
    Martinez A; Fullwood P; Kondo K; Kishida T; Yao M; Maher ER; Latif F
    Mol Pathol; 2000 Jun; 53(3):137-44. PubMed ID: 10897333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational analysis of endothelial cells derived from von Hippel-Lindau-related renal cancer.
    Los M; Kerckhaert OA; Zewald R; van Amstel HK; Voest EE
    J Natl Cancer Inst; 2000 Oct; 92(20):1688-9. PubMed ID: 11036115
    [No Abstract]   [Full Text] [Related]  

  • 19. Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma.
    Gnarra JR; Duan DR; Weng Y; Humphrey JS; Chen DY; Lee S; Pause A; Dudley CF; Latif F; Kuzmin I; Schmidt L; Duh FM; Stackhouse T; Chen F; Kishida T; Wei MH; Lerman MI; Zbar B; Klausner RD; Linehan WM
    Biochim Biophys Acta; 1996 Mar; 1242(3):201-10. PubMed ID: 8603073
    [No Abstract]   [Full Text] [Related]  

  • 20. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients.
    Lubensky IA; Gnarra JR; Bertheau P; Walther MM; Linehan WM; Zhuang Z
    Am J Pathol; 1996 Dec; 149(6):2089-94. PubMed ID: 8952541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.